Showing 9 of 29 recruiting trials for “follicular-lymphoma”
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
👨⚕️ Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center📍 9 sites📅 Started May 2022View details ↗
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
RecruitingNCT05081141 ↗
HHV8 and Solid Organ Transplantation
🏥 Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico📍 1 site📅 Started Sep 2021View details ↗
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
RecruitingNCT03300830 ↗
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
RecruitingNCT03190928 ↗
Clonal Evolution in Follicular Lymphoma
RecruitingNCT02817997 ↗
International Registry for Patients With Castleman Disease
👨⚕️ Joshua Brandstadter, MD, PhD, MSc, University of Pennsylvania📍 1 site📅 Started Oct 2016View details ↗
← PreviousPage 2 of 2
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →